1887

Abstract

Community-acquired pneumonia (CAP) due to is usually mild, but some cases develop a severe life-threatening pneumonia. To investigate the clinical features of severe pneumonia in adults admitted to an intensive care unit, a multi-centre CAP surveillance study was performed. Among all hospitalized CAP cases between January 2000 and December 2004, there were 227 cases with pneumonia without the complication of other pathogens. A total of 13 of the cases required admission to an intensive care unit because of acute respiratory failure (ARF), and the remaining 214 cases (non-ARF) were low to moderately severe. The clinical features of ARF cases were compared with those of non-ARF cases. The underlying conditions in both types of case were identical, whereas clinical findings on admission clearly differed between the two groups. A regimen of an antibiotic effective against was begun on average at 9.3 days after the onset of symptoms in ARF cases, which was significantly later than for non-ARF cases (<0.0001). However, two of the ARF cases progressed to respiratory failure despite the fact that adequate antibiotics were initially administered within 3 days after the onset of symptoms. All ARF cases received corticosteroids with adequate antibiotics, and their condition improved promptly. These results indicate that the clinical features, excluding underlying conditions, clearly differed between severe pneumonia and low to moderately severe pneumonia. The delayed administration of adequate antibiotics may contribute to the severity of pneumonia. Early corticosteroid therapy with adequate antibiotics should be considered.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47119-0
2007-12-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/12/1625.html?itemId=/content/journal/jmm/10.1099/jmm.0.47119-0&mimeType=html&fmt=ahah

References

  1. Blasi F. 2004; Atypical pathogens and respiratory tract infections. Eur Respir J 24:171–181 [CrossRef]
    [Google Scholar]
  2. Chan E. D., Welsh C. H. 1995; Fulminant Mycoplasma pneumoniae pneumonia. West J Med 162:133–142
    [Google Scholar]
  3. Committee for the JRS Guidelines in Management of Respiratory Infections 2005 The JRS Guidelines for the Management of Community-Acquired Pneumonia in Adults (in Japanese) Edited by Matsushima T., Kohno S., Saito A. Tokyo: Japanese Respiratory Society;
    [Google Scholar]
  4. Evengard B., Sandstedt K., Bolske G., Feinstein R., Riesenfelt-Om I., Smith C. I. 1994; Intranasal inoculation of Mycoplasma pulmonis in mice with severe combined immunodeficiency (SCID) causes a wasting disease with grave arthritis. Clin Exp Immunol 98:388–394
    [Google Scholar]
  5. Fine M. J., Auble T. E., Yealy D. M., Hanusa B. H., Weissfeld L. A., Singer D. E., Coley C. M., Marrie T. J., Kapoor W. N. 1997; A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250 [CrossRef]
    [Google Scholar]
  6. Fonseca-Aten M., Rios A. M., Mejias A., Chavez-Bueno S., Katz K., Gomez A. M., McCracken G. H. Jr, Hardy R. D. 2005; Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice. Am J Respir Cell Mol Biol 32:201–210 [CrossRef]
    [Google Scholar]
  7. Foy H. M., Ochs H., Davis S. D., Kenny G. E., Luce R. R. 1973; Mycoplasma pneumoniae infection in patients with immunodeficiency syndromes: report of four cases. J Infect Dis 127:388–393 [CrossRef]
    [Google Scholar]
  8. Fraley D. S., Ruben F. L., Donnelly E. J. 1979; Respiratory failure secondary to Mycoplasma pneumoniae infection. South Med J 72:437–440 [CrossRef]
    [Google Scholar]
  9. Ito S., Abe Y., Kinomoto K., Saitoh T., Kato T., Kohli Y., Kuriyama M., Sakai T., Ishizaki T. 1995; Fulminant Mycoplasma pneumoniae pneumonia with marked elevation of serum soluble interleukin-2 receptor. Intern Med 34:430–435 [CrossRef]
    [Google Scholar]
  10. Kitching A. R., Tipping P. G., Kurimoto M., Holdsworth S. R. 2000; IL-18 has IL-12 independent effects in delayed-type hypersensitivity: studies in cell-mediated crescentic glomerulonephritis. J Immunol 165:4649–4657 [CrossRef]
    [Google Scholar]
  11. Koletsky R. J., Weinstein A. J. 1980; Fulminant Mycoplasma pneumoniae infection. Report of a fatal case, and review of the literature. Am Rev Respir Dis 122:491–496
    [Google Scholar]
  12. Marrie T. J. 1993; Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch Intern Med 153:488–494 [CrossRef]
    [Google Scholar]
  13. Marston B. J., Plouffe J. F., File T. M. Jr, Hackman B. A., Salstrom S.-J., Lipman H. B., Kolczak M. S., Breiman R. F. 1997; Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157:1709–1718 [CrossRef]
    [Google Scholar]
  14. Miyashita N., Fukano H., Okimoto N., Hara H., Yoshida K., Niki Y., Matsushima T. 2002; Clinical presentation of community-acquired Chlamydia pneumoniae pneumonia in adults. Chest 121:1776–1781 [CrossRef]
    [Google Scholar]
  15. Miyashita N., Fukano H., Mouri K., Fukuda M., Yoshida K., Kobashi Y., Niki Y., Oka M. 2005; Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study. J Med Microbiol 54:395–400 [CrossRef]
    [Google Scholar]
  16. Mizutani H., Kitayama T., Hayakawa A., Nagayama E. 1971; Delayed hypersensitivity in Mycoplasma pneumoniae infection. Lancet 1:186–187
    [Google Scholar]
  17. NIHIDSC 2007 Mycoplasma pneumoniae pneumonia National Institute of Health Infectious Disease Surveillance Center; Tokyo, Japan: http://idsc.nih.go.jp/idwr/kanja/weeklygraph/18myco-e.html
    [Google Scholar]
  18. Porath A., Schlaeffer F., Lieberman D. 1997; The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect 34:41–48 [CrossRef]
    [Google Scholar]
  19. Ramirez J. A., Ahkee S., Tolentino A., Miller R. D., Summersgill J. T. 1996; Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae , or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagn Microbiol Infect Dis 24:7–14 [CrossRef]
    [Google Scholar]
  20. Takiguchi Y., Shikama N., Aotsuka N., Koseki H., Terano T., Hirai A. 2001; Fulminant Mycoplasma pneumoniae pneumonia. Intern Med 40:345–348 [CrossRef]
    [Google Scholar]
  21. Tanaka H., Honma S., Abe S., Tamura H. 1996; Effects of interleukin-2 and cyclosporine A on pathologic features in Mycoplasma pneumonia. Am J Respir Crit Care Med 154:1908–1912 [CrossRef]
    [Google Scholar]
  22. Tanaka H., Narita M., Teramoto S., Saikai T., Oashi K., Igarashi T., Abe S. 2002; Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest 121:1493–1497 [CrossRef]
    [Google Scholar]
  23. Tsuruta R., Kawamura Y., Inoue T., Kasaoka S., Sadamitsu D., Maekawa T. 2002; Corticosteroid therapy for hemolytic anemia and respiratory failure due to Mycoplasma pneumoniae pneumonia. Intern Med 41:229–232 [CrossRef]
    [Google Scholar]
  24. Waites K. B., Talkington D. F. 2004; Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 17:697–728 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47119-0
Loading
/content/journal/jmm/10.1099/jmm.0.47119-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error